spacer
home > ebr > autumn 2009 > primum non nocere: first, do no harm
PUBLICATIONS
European Biopharmaceutical Review

Primum non nocere: First, do no harm

 

Ever since the publication of the report, ‘To Err is Human; Building a Safer Health System’, the medical world has begun to open its eyes to the magnitude and impact of errors (1). The report was issued in 1999 by the Institute of Medicine (IOM) of the National Academy of Sciences in the US, and called for a broad effort to improve the situation, which included the reporting of errors and adverse events. With the latter, we mean an injury related to care (diagnosis, treatment, failure, systems and equipment used). The world needed some time to accept that in the Western, more people die due to preventable errors in hospitals than by traffic accidents, or other situations which are generally perceived as being more dangerous.

This report was certainly not the only one published and many followed. In the Netherlands, for example, the President Director of Shell Netherlands, Mr Rein Willems, published a report in 2004 which included four ways to reduce errors by no less than 75 per cent within a period of 15 years. Willems claimed the necessity of the introduction of a certified clinical risk management system and strong governmental supervision.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gian Schiava is Marketing Manager at The Patient Safety Company, where he works on the international expansion of this Dutch company. He has more than 20 years of marketing and sales experience in various industries, varying from office furniture to heavy-duty forklifts. As a member of the Management Team, he is interested in the current challenge to market products that lead to a reduction of incidents and improved patient safety levels, both in large medical hospitals and smaller, specialised healthcare organisations. Gian holds a Bachelor in Economics and undertook post-doctoral studies.
spacer
Gian Schiava
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The Native Antigen Company Introduces New Range of Influenza Antigens

Oxford, UK, 16 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season. The latest influenza antigens will help support development of vaccines and diagnostics as part of the ongoing vaccine reformulation programme, helping to ensure public safety throughout the annual flu season.
More info >>

White Papers

Financial implications of off-site visits in clinical research, perception versus reality

Illingworth Research

The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off-site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off-site nursing more expensive than the traditional site model?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement